234 related articles for article (PubMed ID: 33349293)
1. Androgen use in hereditary angioedema: A critical appraisal and approaches to transitioning from androgens to other therapies.
Johnston DT; Henry Li H; Craig TJ; Bernstein JA; Anderson J; Joseph K; Riedl MA
Allergy Asthma Proc; 2021 Jan; 42(1):22-29. PubMed ID: 33349293
[No Abstract] [Full Text] [Related]
2. An expert panel's review on patients with hereditary angioedema switching from attenuated androgens to oral prophylactic therapy.
Lumry WR; Bernstein JA; Li HH; Levy DS; Jones DH; Padilla BE; Li-Mcleod J; Tachdjian R
Allergy Asthma Proc; 2024 Jan; 45(1):44-49. PubMed ID: 38151740
[No Abstract] [Full Text] [Related]
3. Attenuated androgen discontinuation in patients with hereditary angioedema: a commented case series.
Maurer M; Magerl M; Aygören-Pürsün E; Bork K; Farkas H; Longhurst H; Kiani-Alikhan S; Bouillet L; Boccon-Gibod I; Cancian M; Zanichelli A; Launay D
Allergy Asthma Clin Immunol; 2022 Jan; 18(1):4. PubMed ID: 35027083
[TBL] [Abstract][Full Text] [Related]
4. HAE update: determining optimal patient specific therapy.
Gower RG
Allergy Asthma Proc; 2013; 34(1):7-12. PubMed ID: 23406928
[TBL] [Abstract][Full Text] [Related]
5. Improving patient outcomes in hereditary angioedema: reducing attack frequency using routine prevention with C1 inhibitor concentrate.
Dominas N; Hoffmann TK; Bas M; Greve J
BMJ Case Rep; 2014 May; 2014():. PubMed ID: 24850548
[TBL] [Abstract][Full Text] [Related]
6. Long-term prophylaxis of hereditary angioedema with androgen derivates: a critical appraisal and potential alternatives.
Maurer M; Magerl M
J Dtsch Dermatol Ges; 2011 Feb; 9(2):99-107. PubMed ID: 20946572
[TBL] [Abstract][Full Text] [Related]
7. Clinical manifestations, diagnosis, and treatment of hereditary angioedema: survey data from 94 physicians in Japan.
Ohsawa I; Honda D; Nagamachi S; Hisada A; Shimamoto M; Inoshita H; Mano S; Tomino Y
Ann Allergy Asthma Immunol; 2015 Jun; 114(6):492-8. PubMed ID: 25872948
[TBL] [Abstract][Full Text] [Related]
8. Assessment of hereditary angioedema treatment risks.
Kalaria S; Craig T
Allergy Asthma Proc; 2013; 34(6):519-22. PubMed ID: 24169059
[TBL] [Abstract][Full Text] [Related]
9. Current options for prophylactic treatment of hereditary angioedema in the United States: patient-based considerations.
Gower RG; Lumry WR; Davis-Lorton MA; Johnston DT; Busse PJ
Allergy Asthma Proc; 2012; 33(3):235-40. PubMed ID: 22584192
[TBL] [Abstract][Full Text] [Related]
10. Anabolic androgen use in the management of hereditary angioedema: Not so cheap after all.
Tse KY; Zuraw BL; Chen Q; Christiansen SC
Ann Allergy Asthma Immunol; 2017 Apr; 118(4):456-460.e1. PubMed ID: 28283277
[TBL] [Abstract][Full Text] [Related]
11. Hereditary angioedema therapies in the United States: movement toward an international treatment consensus.
Riedl M
Clin Ther; 2012 Mar; 34(3):623-30. PubMed ID: 22386830
[TBL] [Abstract][Full Text] [Related]
12. Real-world cohort study of adult and pediatric patients treated for hereditary angioedema in the United States.
Tachdjian R; Johnson KE; Casso D; Oliveria SA; Devercelli G; Jain G
Allergy Asthma Proc; 2020 May; 41(3):172-182. PubMed ID: 32375961
[No Abstract] [Full Text] [Related]
13. Tolerability and Effectiveness of 17-α-Alkylated Androgen Therapy for Hereditary Angioedema: A Re-examination.
Zuraw BL; Davis DK; Castaldo AJ; Christiansen SC
J Allergy Clin Immunol Pract; 2016; 4(5):948-955.e15. PubMed ID: 27329469
[TBL] [Abstract][Full Text] [Related]
14. Discrepancies between guidelines and international practice in treatment of hereditary angioedema.
Dispenza MC; Craig TJ
Allergy Asthma Proc; 2012; 33(3):241-8. PubMed ID: 22584193
[TBL] [Abstract][Full Text] [Related]
15. Hereditary angiodema: a current state-of-the-art review, IV: short- and long-term treatment of hereditary angioedema: out with the old and in with the new?
Zuraw BL
Ann Allergy Asthma Immunol; 2008 Jan; 100(1 Suppl 2):S13-8. PubMed ID: 18220147
[TBL] [Abstract][Full Text] [Related]
16. Long-term prophylaxis in hereditary angioedema management: Current practices in France and unmet needs.
Bouillet L; Fain O; Armengol G; Aubineau M; Blanchard-Delaunay C; Dalmas MC; De Moreuil C; Du Thanh A; Gobert D; Guez S; Hoarau C; Jaussaud R; Jeandel PY; Maillard H; Marmion N; Masseau A; Menetrey C; Ollivier Y; Pelletier F; Plu-Bureau G; Sailler L; Vincent D; Bouquillon B; Verdier E; Clerson P; Boccon-Gibod I; Launay D
Allergy Asthma Proc; 2022 Sep; 43(5):406-412. PubMed ID: 35868842
[No Abstract] [Full Text] [Related]
17. Hereditary angioedema: diagnosis and management-a perspective for the dermatologist.
Parish LC
J Am Acad Dermatol; 2011 Oct; 65(4):843-850. PubMed ID: 21550133
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human C1 esterase inhibitor for the treatment of hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE).
Sabharwal G; Craig T
Expert Rev Clin Immunol; 2015 Mar; 11(3):319-27. PubMed ID: 25669442
[TBL] [Abstract][Full Text] [Related]
19. Physician and patient perspectives on the management of hereditary angioedema: a survey on treatment burden and needs.
Riedl MA; Craig TJ; Banerji A; Aggarwal K; Best JM; Rosselli J; Hahn R; Radojicic C
Allergy Asthma Proc; 2021 May; 42(3):S17-S25. PubMed ID: 33980329
[TBL] [Abstract][Full Text] [Related]
20. Hereditary angioedema: a clinical review for the otolaryngologist.
Anon JB
Ear Nose Throat J; 2011 Jan; 90(1):32-9. PubMed ID: 21229509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
